Power morcellation-induced dissemination of sarcomatous component arising in leiomyoma

J Obstet Gynaecol Res. 2018 Sep;44(9):1843-1849. doi: 10.1111/jog.13694. Epub 2018 Jul 5.

Abstract

In 2014, the US Food and Drug Administration issued a safety communication warning against the use of power morcellators during laparoscopic hysterectomy or myomectomy. We report a case of peritoneal leiomyosarcomatosis attributable to power morcellation. A 49-year-old nulligravid woman presented with a huge uterine tumor measuring 15 × 8 cm that was diagnosed as benign leiomyoma on magnetic resonance imaging. The uterine tumor had shrunk to 13 × 7 cm after five treatment courses with a gonadotropin-releasing hormone agonist. She underwent laparoscopic hysterectomy using power morcellation; postoperative pathological diagnosis was benign leiomyoma. After 6 months, urinary ascites developed because of right ureteral rupture. She underwent laparotomy and was diagnosed with peritoneal leiomyosarcomatosis. Meticulous and thorough reevaluation of the morcellated specimens revealed a small component of leiomyosarcoma. Use of power morcellation should be minimized until the advent of novel methods that can perfectly differentiate benign from malignant uterine tumors preoperatively.

Keywords: histology; hysterectomy; laparoscopy; leiomyosarcomatosis; magnetic resonance imaging.

Publication types

  • Case Reports

MeSH terms

  • Female
  • Humans
  • Leiomyoma / surgery*
  • Leiomyosarcoma / etiology*
  • Leiomyosarcoma / pathology
  • Middle Aged
  • Morcellation / adverse effects*
  • Uterine Myomectomy / adverse effects*
  • Uterine Myomectomy / methods
  • Uterine Neoplasms / surgery*